Future Cannabis Strategies Europe 2022

• Restoration of THC limits in the field to 0.3%
• Changes to Feed Register and CosIng Cosmetics Database
• Adoption of EU regulation on the maximum level of THC in food (seeds, dry food & oil)
• ACMD CBD products report 12/21
• Novel Food consortium application update – preliminary results from tox studies

• Creating considered and targeted brands and products that use CBD, or creating CBD brands?
• Democratising cannabis by targeting markets who need more choice and care
• Growing the brand portfolio based on gaps in the market to ensure there is sizeable demand
• Focussing on the “professionalisation” of the cannabis industry to guarantee a secure and fruitful future

• How have the highs and lows of cannabis on the stock market affected the path to greater investment?
• What do we need to understand about the market financials to predict the future?
• Which critical milestones and regulations are helping to accelerate the growth of the industry and open doors to funding opportunity?
• Niche or mainstream? What is the importance of product innovation when it comes to finding funding?
• What is the best way to use funding in the industry to achieve better distribution and create a more powerful voice?
• M&A, or investment – what is the golden nugget here?
• How can brands make the product and brand scalable to ensure maximum possibility when searching for investment?

• Discovering the Israeli cannabis market to understand the development in Israel and surrounding areas
• Looking at the import and export potential from Israel to the EU
• Finding opportunity in medical vs recreational cannabis in today’s market
• Understanding the direction of the cannabis market to better strategise and find partners of quality

• Improving patient access Europe wide to make cannabis treatments more accessible
• The medical cannabis landscape in the United Kingdom
• Creating medical prescriptions for various health conditions to help on the path to improved health
• Encouraging the progress of patient access in Europe to ensure holistic treatment availability
• Educating the patients and practices on the benefits of cannabis and trial results to guarantee confidence in cannabis treatments

• Overcoming the stigma around cannabis in support of social and economic development
• Creating transparency in the industry to move away from stigma and towards a category that delivers its promises
• Supplying evidence-based studies on how cannabis works on improving people’s lives
• Setting product transparency through innovative technologies to educate consumers (data and dosing)
• Protecting your business through a strong sustainability message and strategy

• Looking at the retail landscape for the cannabis sector from its infancy to growing popularity
• Merging forces to create a brand and category of strength
• Taking lessons from the real retail world to devise a strategy for market launch and success

There is global concern over the quality and toxicological safety of cannabis plant material, extracted oils and end user formulations. To address this, several leading organisations have introduced analytical tests to show that any residues present, are below those concentrations at which they become a concern. Such residues might include heavy metals, residual solvents, pesticides and mycotoxins for example.

A survey of global country regulations reveals that some countries/states have specified limits dictating whether a product is deemed safe for public use, but these limits vary depending on the geographical location. For example, Canada and Australia have country regulations, and the United States is focused on state regulation. But what about Europe and the general position needed to ensure that a cannabis supply chain is safe?

For commodities that are to be used within the EU community, the interest has seen a push towards having materials conform to the EU Pharmacopeia for medicinal cannabis.

This presentation outlines the core chemical analysis programs that need to be in place in order to meet those EU Pharmacopeia standards, including the analysis of pesticides aligned with EU. Ph 2.8.13 requirements.

• How can we create positively received cannabis niches in already existing successful categories like alcohol or no and low?
• What are the key factors to take into consideration when trying to leverage a profitable product model in the cannabis space?
• How can we give the consumer extraordinary experiences to create products that leave impact and satisfaction?
• What can drink brands do to leverage the social occasion to create unique and exciting beverages?
• How can we target the new age consumer with never seen before beverage options?
• How open is the consumer and the retailer to adult cannabis products and how can the industry help to carve new spaces in the market?
• What can we see in today’s market that demonstrates the need to implement cannabis derived products into the drinking occasion?

• The challenges of building a brand in an uncertain and developing regulatory environment
• Implications of Novel Foods on business strategy and innovation
• Navigating the policies of media owners and financial institutions
• An outlook on future developments and the next level of challenges for the industry to tackle

• What can we expect from next-generation cannabis products?
• How important is it to implement consumer-led innovation to develop accessible cannabis products?
• Understanding why consumer demand for CBD products soared during lockdown and how this has transitioned into a more open market?
• How can we leverage cannabis ingredients as a “value added” proposition to increase consumer demand?
• What does the future of cannabis NPD look like and how are companies building on these ideas while restrictions are still in place?

• Understanding the JuicyFields mission: removing stigmas around the industry and the higher purpose that holds the vision together
• Looking at the ongoing involvement in the medical cannabis industry to understand how we are changing the status quo
• Exploring relationships with our partners and cultivators
• Celebrating achievements and our international approach
• Planning the next 12 months and beyond

• How can we capitalize on the increase in awareness of cannabis products to ensure growth in demand and push retailers and governments to support the supply of cannabis derived products to market?
• What are the medium to long term effects the pandemic had on consumer and patient behaviors that may affect the success of the cannabis?
• Is it possible to create an industry of collaboration and healthy competition to ensure doors to tight regulations are increasingly opened?
• How are we responding to the need and demand for more cannabis derived products cross category to increase accessibility and NPD?
• What can we do to open opportunities to the consumer / patient to set the tone for a healthier and more accessible cannabis market?
• What is the role of the retailer to get the product to the consumer – are we working together for consumer education and consumer use?

• Pushing for capital markets for sustainable cannabis practices and growth
• Looking at pockets of opportunity in FMCG and medical to identify areas of potential
• Understanding best use of practice to monetise, industrialise the plant to achieve greater success
• Taking inspiration from successful cannabis production and routes to market to innovate and succeed
• Understanding how the industry is being shaped to better manage the cannabis landscape

• Challenges in the UK and European Cannabis markets
• Medicalisation of Cannabis: Introducing Cannabis as a viable medicine by way of product innovation

• Considering the potential of cannabis thematic investing to impulse the category to greater strengths
• Understanding the global trends of the cannabis market to predict the future
• Championing the cannabis sector through modern portfolio investment to capitalise on the different categories of the cannabis industry

• LC-MS/MS for pesticide and mycotoxin analysis
• Advances in instrument technology
• Importance of sample preparation and good laboratory practice

• Where does CBD now sit in the European cannabis sector following various court rulings and regulatory developments? What do we expect for 2022 and beyond?
• How will a consumer of the CBD cannabis sector interact with the growing medicinal market, and a future adult-use consumer market for cannabis in Europe? What is the expected timetable for opening up?
• Despite regulatory issues, how is the market for consumer CBD products developing in Europe? As products become more prevalent across mainstream retail, is CBD growing up?
• What is the future of the market for CBD and other functional wellness products in Europe this year and beyond?

• Tapping into an industry driven by beauty, antiaging and health and wellness to create a product line that offers value added benefits
• Understanding the role of sustainability in cosmeceuticals to address consumer concerns on people, planet through NPD
• Creating high quality cosmetics backed by clinical efficacy to create products that consumers love and trust
• Looking at the need for premiumization to build consumer trust with CBD
• Pairing cannabis with beauty effectively to create added value skin care products that appeal to the consumer and keep the space exciting

• Looking at the keys to success of a maturing cannabis market to create better brands and healthier market space
• Navigating THC NPD to successfully launch more credible and effective products in the category
• Positioning cannabis within the health space to ensure that cannabis demonstrates its understanding of consumer needs
• Securing brands and quality whilst leveraging the “low barriers” to entry to find opportunities that prove beneficial to the category

• Getting clear on what’s working to build a strategy for success
• Understanding the drivers behind cannabis product purchasing to continue to drive the category from strength to strength
• Spotting financial opportunity in global contexts to make waves across the continents